S-1/A: Azitra, Inc. Announces Public Offering of Up to $10 Million in Units

Azitra, Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its S-1 registration statement for a public offering of up to 3,115,265 units, each consisting of one share of common stock or one pre-funded warrant and two Class A warrants, aiming to raise up to $10 million.

Summary

• Azitra, Inc. is offering up to 3,115,265 units to the public.
• Each unit consists of one share of common stock or one pre-funded warrant and two Class A warrants.
• The assumed public offering price per unit is $3.21, based on the last reported sale price of Azitra's common stock on July 11, 2024.
• The Class A warrants have an initial exercise price of $3.21 per share, subject to a potential reset after 30 days based on the trailing five-day VWAP, and will expire five years from the issuance date.
• The offering is being conducted on a 'best efforts' basis, meaning there is no guarantee that all units will be sold.
• The company estimates net proceeds of approximately $8.95 million if all securities are sold, after deducting placement agent fees and estimated offering expenses.
• Azitra intends to use the net proceeds for working capital and general corporate purposes.
• The company believes that the net proceeds, along with existing cash, will meet capital needs until February 2025 if $8.95 million is raised, November 2024 if $5.23 million is raised, and October 2024 if $3.37 million is raised.
• Azitra is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology.
• The company's lead product candidates are ATR-12 for Netherton syndrome and ATR-04 for papulopustular rash in cancer patients undergoing EGFRi therapy.

Sentiment

Score: 4

Explanation: The sentiment is relatively low due to the company's early stage, ongoing losses, and the uncertainty associated with a 'best efforts' offering. However, the innovative approach, partnerships, and potential market growth provide some positive aspects.

Positives

• Azitra has a proprietary platform that includes a microbial library of approximately 1,500 unique bacterial strains.
• The company has partnerships with leading academic centers, including Carnegie Mellon University and the Fred Hutchinson Cancer Center.
• Azitra holds an exclusive, worldwide license from Fred Hutch for its SyngenicDNA Minicircle Plasmid (SyMPL) technologies.
• The company's management team has significant experience in discovering, developing, manufacturing, and commercializing therapeutics.
• Azitra's lead product candidate, ATR-12, has received Rare Pediatric Disease Designation from the FDA.
• The company has a Joint Development Agreement with Bayer, a major life science company.
• The dermatology drug market is predicted to grow at a compound annual growth rate of 8.8% through 2030, according to Vision Research Reports.

Negatives

• Azitra is an early-stage company with a history of significant operating losses and anticipates continued operating losses.
• The offering is being made on a 'best efforts' basis, and the company may receive significantly less in net proceeds than the estimated $8.95 million.
• The company will need additional financing to execute its business plan, which may not be available on reasonable terms or at all.
• The clinical and commercial utility of Azitra's microbial library and genetic engineering platform is uncertain.
• The company's product candidates are in early stages of development and will require extensive additional testing.
• Azitra is completely dependent on third parties to manufacture its product candidates for commercial sale.
• There is no public market for the Class A Warrants or Pre-Funded Warrants, and one is not expected to develop.

Risks

• Investors may lose all of their investment.
• Additional financing needed to execute the business plan may not be available on reasonable terms or at all.
• The offering is 'best efforts,' so the company may receive significantly less in net proceeds, providing only limited working capital.
• The clinical and commercial utility of the company's microbial library and genetic engineering platform is uncertain.
• Product candidates are in early stages and require extensive additional testing.
• The company is dependent on third parties for manufacturing.
• The business model includes out-licensing, which is a lengthy process subject to risks outside the company's control.
• Loss of key personnel could harm the business.
• Product liability lawsuits could result in substantial liabilities.
• Information technology system failures or security breaches could harm operations.
• The company faces significant competition.
• Success depends on obtaining marketing approval from the FDA and foreign regulatory authorities.
• Clinical trials may fail to demonstrate safety and efficacy.
• Preclinical study results may not predict future results.
• Even with regulatory approval, successful commercialization is not guaranteed.
• Legislation may increase the difficulty and cost of obtaining marketing approval and affect prices.
• Protecting intellectual property is difficult and costly.
• Product candidates may infringe on others' intellectual property rights.
• An active, liquid, and orderly trading market for shares may not develop.
• Future capital raises may dilute ownership and have other adverse effects.
• The market price of shares may fluctuate.
• Failure to maintain effective internal control over financial reporting could impact financial reporting accuracy and fraud prevention.
• There is no market for Class A Warrants or Pre-Funded Warrants.
• Holders of Class A Warrants and Pre-Funded Warrants have no rights as common stockholders until exercise.
• The company ratified certain corporate actions, but challenges to the validity of the ratification could still be made.
• Charter documents and Delaware law may inhibit a takeover.
• The market price of shares may fluctuate due to various factors, including market conditions and company performance.
• Provisions of the Class A Warrants could discourage a third-party acquisition.
• The Class A Warrants may adversely affect the market price of common stock and make business combinations more difficult.
• The Class A Warrants are speculative in nature.
• Future equity offerings may cause dilution.
• The company may not receive any meaningful amount of additional funds upon the exercise of the Class A Warrants and Pre-Funded Warrants.
• Significant holders of common stock may not be permitted to exercise Pre-Funded Warrants.
• Failure to meet NYSE American listing requirements could result in delisting.
• Shares eligible for future sale may adversely affect the market.
• The company has not paid dividends and has no immediate plans to do so.
• Equity research analysts may not publish research on the company, or may issue unfavorable commentary.
• The company is subject to a prohibition against engaging in variable transactions which might be applicable to this offering.

Future Outlook

Azitra plans to continue advancing its lead product candidates, ATR-12 and ATR-04, through clinical trials and expects to report initial safety results for ATR-12 in the second half of 2024. The company also intends to file an IND for ATR-04 by mid-2024 and commence a Phase 1b trial in the fourth quarter of 2024. Additionally, Azitra aims to broaden its platform by exploring strategic partnerships and leveraging academic collaborations to expand its research and development pipeline. The company is also planning to complete lead optimization and IND-enabling studies for ATR-01 in 2024, with an IND filing target in the second half of 2025.

Industry Context

Azitra's announcement comes amid a growing dermatology market, which surpassed $17 billion in 2021 and is projected to grow at a CAGR of 8.8% through 2030. The company's focus on precision dermatology using engineered proteins and live biotherapeutics aligns with the industry's increasing interest in novel treatments for skin diseases. The collaboration with Bayer and partnerships with academic institutions further highlight Azitra's position in the evolving landscape of dermatological therapies.

Comparison to Industry Standards

• Azitra's approach to developing engineered proteins and live biotherapeutic products for precision dermatology is innovative compared to traditional treatments.
• Many companies focus on small molecule drugs or biologics, while Azitra's use of engineered microbes is relatively unique in the dermatology space.
• For example, companies like Pfizer and AbbVie have established dermatology portfolios but primarily focus on traditional approaches.
• Azitra's lead candidate ATR-12 targets Netherton syndrome, a rare disease. This is similar to other companies focusing on rare diseases, such as Amryt Pharma, which has a product approved for epidermolysis bullosa, another rare skin disorder.
• Azitra's collaboration with Bayer is notable. Joint development agreements are common in the industry, such as the partnership between Novartis and Amgen for migraine treatments, but Azitra's focus on microbial strains is less common.
• The company's work on papulopustular rash due to EGFR inhibitors (ATR-04) addresses a significant unmet need in oncology, similar to how companies like Puma Biotechnology are developing therapies to manage side effects of cancer treatments.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's continued development and potential growth if the offering is successful.
• Customers, particularly patients with Netherton syndrome and cancer patients experiencing papulopustular rash, may benefit from the development of new treatments.
• Suppliers and creditors may be impacted by the company's financial condition and ability to secure additional funding.
• Successful development and commercialization of Azitra's product candidates could provide significant benefits to patients with unmet medical needs in dermatology.

Next Steps

• Complete the public offering of units.
• Report initial safety results for the Phase 1b clinical trial of ATR-12 in the second half of 2024.
• Submit an IND for ATR-04 by mid-2024.
• Commence a Phase 1b clinical trial for ATR-04 in the fourth quarter of 2024.
• Continue lead optimization and IND-enabling studies for ATR-01, targeting an IND filing in the second half of 2025.
• Further develop the two selected strains with Bayer under the Joint Development Agreement.
• Seek additional funding through various financing sources to support operations and development activities.

Key Dates

Keywords

precision dermatology, engineered proteins, live biotherapeutic products, microbial library, Staphylococcus epidermidis, genetic engineering, Netherton syndrome, EGFRi therapy, papulopustular rash, ichthyosis vulgaris, clinical trials, FDA approval, biopharmaceutical, IPO, public offering